Cara Therapeutics (CARA) Tops Q2 EPS by 18c

Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.08), $0.18 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $23 million versus the consensus estimate of $21.11 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Worthington Enterprises raises dividend 5%, adds board member